Index -
P/E -
EPS (ttm) -2.50
Insider Own 0.97%
Shs Outstand 492.85M
Perf Week 3.30%
Market Cap 6.66B
Forward P/E 12.73
EPS next Y 1.06
Insider Trans 0.80%
Shs Float 489.28M
Perf Month -12.70%
Income -1231.00M
PEG -
EPS next Q 0.26
Inst Own 98.02%
Short Float 3.17%
Perf Quarter -8.92%
Sales 4.42B
P/S 1.51
EPS this Y 3.25%
Inst Trans -3.01%
Short Ratio 3.75
Perf Half Y 52.89%
Book/sh 12.63
P/B 1.07
EPS next Y 15.11%
ROA -8.25%
Short Interest 15.52M
Perf Year 48.51%
Cash/sh 0.71
P/C 18.91
EPS next 5Y 8.87%
ROE -18.22%
52W Range 7.88 - 16.88
Perf YTD -9.60%
Dividend Est. -
P/FCF 50.81
EPS past 5Y -
ROI -10.20%
52W High -20.20%
Beta 1.39
Dividend TTM -
Quick Ratio 1.35
Sales past 5Y 9.00%
Gross Margin 43.88%
52W Low 70.94%
ATR (14) 0.49
Dividend Ex-Date -
Current Ratio 2.75
EPS Y/Y TTM -1484.90%
Oper. Margin 7.38%
RSI (14) 40.25
Volatility 3.44% 3.47%
Employees 9800
Debt/Eq 0.95
Sales Y/Y TTM -0.02%
Profit Margin -27.87%
Recom 2.00
Target Price 17.75
Option/Short Yes / Yes
LT Debt/Eq 0.94
EPS Q/Q -158.91%
Payout -
Rel Volume 0.95
Prev Close 13.15
Sales Surprise 3.33%
EPS Surprise -23.44%
Sales Q/Q 4.76%
Earnings May 08 BMO
Avg Volume 4.14M
Price 13.47
SMA20 -3.43%
SMA50 -11.30%
SMA200 2.82%
Trades
Volume 3,915,646
Change 2.43%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-05-24 Upgrade
Stifel
Hold → Buy
$13 → $20
Dec-19-23 Initiated
Jefferies
Buy
$17
Dec-15-23 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$16
Dec-07-23 Initiated
Exane BNP Paribas
Outperform
$18
Apr-20-23 Upgrade
Barclays
Equal Weight → Overweight
$14
Aug-18-22 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$37 → $22
Aug-16-22 Downgrade
JP Morgan
Overweight → Neutral
$28 → $24
Jul-21-22 Downgrade
Goldman
Buy → Sell
$32 → $19
Jul-12-22 Initiated
Piper Sandler
Neutral
$22
Nov-18-21 Initiated
Morgan Stanley
Overweight
$40
Oct-28-21 Downgrade
Stifel
Buy → Hold
$37 → $34
Aug-05-21 Resumed
Credit Suisse
Outperform
$38
Jun-15-21 Upgrade
Cleveland Research
Underperform → Neutral
May-11-21 Upgrade
Gabelli & Co
Hold → Buy
May-11-21 Upgrade
Barclays
Underweight → Equal Weight
$25 → $29
Apr-15-21 Initiated
Stifel
Buy
$37
Mar-22-21 Downgrade
Gabelli & Co
Buy → Hold
Feb-26-21 Upgrade
Credit Suisse
Neutral → Outperform
$33 → $38
Dec-09-20 Downgrade
Argus
Buy → Hold
Nov-09-20 Downgrade
Barclays
Overweight → Underweight
$35 → $25
Show Previous Ratings
Apr-25-24 11:27AM
Apr-23-24 08:30AM
Apr-21-24 10:39AM
Apr-17-24 08:00AM
Apr-01-24 07:00AM
06:39AM
Loading…
06:39AM
06:30AM
Mar-31-24 11:37PM
Mar-13-24 02:21PM
Mar-12-24 07:00PM
Mar-05-24 10:15AM
Mar-04-24 08:33AM
Feb-29-24 03:30PM
01:08PM
08:00AM
07:03AM
Loading…
07:03AM
Feb-28-24 10:58AM
Feb-26-24 11:41PM
(Thomson Reuters StreetEvents)
02:15PM
09:30AM
06:52AM
06:27AM
Feb-22-24 08:00AM
Feb-21-24 09:15AM
Feb-19-24 10:00AM
Feb-15-24 07:00AM
Feb-13-24 01:09PM
Feb-09-24 10:15AM
Feb-08-24 02:46PM
08:00AM
01:25PM
Loading…
Feb-07-24 01:25PM
Feb-05-24 07:01AM
(The Wall Street Journal) +7.94%
06:48AM
06:36AM
06:33AM
06:33AM
Jan-18-24 08:22PM
Jan-17-24 08:30AM
Jan-08-24 07:35AM
Jan-02-24 08:33AM
Jan-01-24 09:15AM
Dec-19-23 08:00AM
Dec-14-23 05:08PM
Dec-08-23 09:00AM
Dec-07-23 04:37PM
Nov-27-23 08:00AM
Nov-10-23 05:20PM
Nov-09-23 03:49AM
Nov-08-23 04:03PM
12:21AM
(Thomson Reuters StreetEvents)
Nov-07-23 01:45PM
09:30AM
07:31AM
07:03AM
06:33AM
Nov-02-23 11:33AM
08:00AM
07:16AM
Nov-01-23 09:00AM
Oct-30-23 04:32PM
Oct-17-23 04:57PM
08:00AM
Oct-09-23 09:55AM
Oct-06-23 12:05PM
08:36AM
Oct-05-23 11:22AM
Oct-04-23 06:30AM
Sep-19-23 06:20AM
04:23AM
Sep-12-23 06:40AM
Sep-07-23 04:15PM
Sep-05-23 05:00PM
Aug-09-23 10:36AM
07:56AM
Aug-08-23 12:16AM
(Thomson Reuters StreetEvents)
Aug-07-23 02:30PM
12:34PM
09:30AM
07:50AM
06:33AM
Aug-02-23 07:10AM
06:55AM
Market Digest: CCI, CCI, ASH, ITW, MAR, MDC, SHEL, SANM, LEA, ANET, ELAN
(Argus Research)
Jul-20-23 08:00AM
Jul-18-23 08:00AM
Jul-17-23 08:48AM
Jul-14-23 06:29PM
12:21PM
Jul-13-23 06:30PM
05:24PM
Jul-01-23 09:21AM
Jun-24-23 03:19PM
Jun-05-23 08:00AM
May-30-23 06:20PM
May-25-23 08:00AM
May-16-23 11:13AM
May-09-23 06:30PM
11:25AM
07:55AM
06:34AM
May-08-23 05:45PM
Elanco Animal Health, Inc. innovates, develops, manufactures, and markets products for pets and farm animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of a broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded in 1954 and is headquartered in Greenfield, IN.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
DOYLE WILLIAM F Director Mar 08 '24 Buy 16.30 15,000 244,500 61,330 Mar 12 04:32 PM Harrington Michael J Director Mar 08 '24 Buy 16.29 3,100 50,494 77,594 Mar 12 04:30 PM HOOVER R DAVID Director Mar 06 '24 Buy 16.14 20,000 322,808 185,000 Mar 08 05:09 PM
Index -
P/E -
EPS (ttm) -1.81
Insider Own 10.09%
Shs Outstand 107.08M
Perf Week 16.03%
Market Cap 1.53B
Forward P/E -
EPS next Y -1.76
Insider Trans -0.10%
Shs Float 96.75M
Perf Month -1.60%
Income -192.74M
PEG -
EPS next Q -0.41
Inst Own 81.15%
Short Float 6.24%
Perf Quarter -3.21%
Sales 525.66M
P/S 2.90
EPS this Y 15.90%
Inst Trans 2.97%
Short Ratio 4.70
Perf Half Y 6.69%
Book/sh 3.34
P/B 4.25
EPS next Y -7.23%
ROA -16.79%
Short Interest 6.04M
Perf Year -78.27%
Cash/sh 8.12
P/C 1.75
EPS next 5Y -
ROE -48.70%
52W Range 10.87 - 83.60
Perf YTD -4.96%
Dividend Est. -
P/FCF -
EPS past 5Y -22.97%
ROI -20.19%
52W High -83.03%
Beta 0.61
Dividend TTM -
Quick Ratio 5.99
Sales past 5Y 17.16%
Gross Margin 74.97%
52W Low 30.54%
ATR (14) 0.81
Dividend Ex-Date -
Current Ratio 6.26
EPS Y/Y TTM -120.47%
Oper. Margin -45.63%
RSI (14) 57.95
Volatility 7.34% 5.61%
Employees 1453
Debt/Eq 1.66
Sales Y/Y TTM 0.61%
Profit Margin -36.67%
Recom 2.14
Target Price 25.50
Option/Short Yes / Yes
LT Debt/Eq 1.66
EPS Q/Q 28.06%
Payout -
Rel Volume 1.23
Prev Close 12.74
Sales Surprise 5.37%
EPS Surprise 14.29%
Sales Q/Q 13.36%
Earnings May 02 BMO
Avg Volume 1.28M
Price 14.19
SMA20 9.31%
SMA50 -0.27%
SMA200 -17.78%
Trades
Volume 1,575,213
Change 11.38%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-20-23 Resumed
JP Morgan
Neutral
$15
Aug-28-23 Downgrade
H.C. Wainwright
Buy → Neutral
$85 → $25
Aug-08-23 Upgrade
Piper Sandler
Neutral → Overweight
$45
Aug-04-23 Initiated
SVB Securities
Outperform
$51
Jul-31-23 Upgrade
Evercore ISI
Underperform → In-line
$33
Jun-07-23 Upgrade
Wedbush
Underperform → Neutral
$53 → $46
May-16-23 Upgrade
Wells Fargo
Equal Weight → Overweight
$70 → $104
Mar-17-23 Downgrade
JP Morgan
Neutral → Underweight
$99 → $50
Jan-06-23 Downgrade
Wells Fargo
Overweight → Equal Weight
$89 → $107
Jan-05-23 Reiterated
H.C. Wainwright
Buy
$100 → $140
Nov-29-22 Upgrade
Wells Fargo
Equal Weight → Overweight
$74 → $89
Oct-24-22 Downgrade
Piper Sandler
Overweight → Neutral
$90 → $70
Jul-05-22 Downgrade
Evercore ISI
In-line → Underperform
May-16-22 Initiated
H.C. Wainwright
Buy
$115
Feb-08-22 Initiated
Loop Capital
Buy
$200
Feb-02-22 Upgrade
Oppenheimer
Perform → Outperform
$98
Jan-20-22 Upgrade
Truist
Hold → Buy
$125
Jan-03-22 Upgrade
Evercore ISI
Underperform → In-line
$82
Jul-01-21 Downgrade
Mizuho
Buy → Neutral
Apr-14-21 Downgrade
Wedbush
Neutral → Underperform
$159 → $154
Show Previous Ratings
Today 01:00AM
May-02-24 01:19PM
11:56AM
08:45AM
08:25AM
07:28AM
Loading…
07:28AM
(Associated Press Finance)
07:01AM
07:00AM
Apr-25-24 10:01AM
Apr-24-24 10:45AM
Apr-05-24 07:00AM
Apr-04-24 11:33AM
Apr-01-24 12:00PM
07:00AM
Mar-30-24 06:34AM
11:50AM
Loading…
Mar-28-24 11:50AM
05:01AM
Mar-27-24 04:08PM
(Investor's Business Daily) +12.01%
09:29AM
09:16AM
(Investor's Business Daily)
07:14AM
07:12AM
07:05AM
07:00AM
Mar-13-24 09:55AM
Mar-11-24 07:00AM
Feb-23-24 11:43AM
Feb-22-24 12:15PM
08:25AM
07:36AM
07:23AM
Loading…
07:23AM
(Associated Press Finance)
07:00AM
Jan-19-24 07:46AM
Jan-18-24 02:19PM
07:00AM
Jan-11-24 09:55AM
Jan-09-24 07:00AM
Jan-08-24 07:00AM
Jan-04-24 04:05PM
Dec-27-23 07:00AM
Dec-08-23 04:09AM
Dec-04-23 04:46PM
Nov-28-23 10:51AM
07:30AM
Nov-21-23 07:00AM
Nov-14-23 09:09AM
Nov-10-23 08:00AM
Nov-03-23 06:45AM
Oct-30-23 02:04AM
Oct-28-23 08:39AM
Oct-26-23 04:35PM
11:00AM
08:52AM
08:30AM
07:24AM
(Associated Press Finance)
07:00AM
Oct-15-23 06:05PM
Oct-12-23 08:00AM
Oct-02-23 07:00AM
Sep-29-23 05:00PM
Sep-18-23 11:47AM
Sep-08-23 04:01PM
Sep-06-23 02:27PM
Sep-04-23 09:30AM
Aug-31-23 06:52PM
09:55AM
Aug-29-23 06:31PM
Aug-28-23 05:15PM
04:08PM
(Investor's Business Daily)
02:19PM
(Investor's Business Daily)
12:21PM
12:16PM
12:10PM
11:47AM
09:34AM
07:27AM
07:10AM
07:00AM
Aug-25-23 08:20AM
07:00AM
Aug-15-23 09:30AM
Aug-13-23 05:49PM
Aug-09-23 10:45AM
05:10AM
Aug-08-23 04:11PM
10:02AM
Aug-04-23 09:38AM
Aug-01-23 03:54PM
Jul-27-23 06:56PM
11:30AM
08:15AM
07:07AM
07:00AM
Jul-25-23 10:01AM
Jul-21-23 08:00AM
Jul-06-23 01:17PM
Jul-03-23 08:00AM
Jun-12-23 09:30AM
05:39AM
Jun-09-23 09:45AM
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GROENHUYSEN WILHELMUS CM Chief Operating Officer Mar 04 '24 Sale 16.01 1,217 19,484 251,235 Mar 05 04:09 PM Leonard Frank X EVP, Pres., Novocure Oncology Mar 04 '24 Sale 16.01 840 13,448 160,098 Mar 05 04:08 PM GROENHUYSEN WILHELMUS CM Chief Operating Officer Mar 01 '24 Sale 16.03 2,107 33,769 252,452 Mar 05 04:09 PM Leonard Frank X EVP, Pres., Novocure Oncology Mar 01 '24 Sale 16.03 1,679 26,909 160,938 Mar 05 04:08 PM GROENHUYSEN WILHELMUS CM Chief Operating Officer Feb 28 '24 Sale 16.14 2,303 37,177 254,559 Feb 29 04:28 PM Leonard Frank X EVP, Pres., Novocure Oncology Feb 28 '24 Sale 16.14 2,078 33,545 162,617 Feb 29 04:38 PM Shah Pritesh Chief Growth Officer Nov 07 '23 Sale 12.65 382 4,832 124,511 Nov 08 04:22 PM Cordova Ashley Chief Financial Officer Nov 02 '23 Option Exercise 11.46 175 2,006 117,618 Nov 02 04:20 PM Cordova Ashley Chief Financial Officer Oct 31 '23 Option Exercise 9.58 17,793 170,447 117,443 Nov 02 04:20 PM Cordova Ashley Chief Financial Officer Sep 01 '23 Sale 21.82 883 19,265 99,650 Sep 05 04:24 PM GROENHUYSEN WILHELMUS CM Chief Operating Officer Sep 01 '23 Sale 21.82 294 6,414 209,825 Sep 05 04:24 PM Shah Pritesh Chief Growth Officer Sep 01 '23 Sale 21.82 273 5,956 124,893 Sep 05 04:23 PM Cordova Ashley Chief Financial Officer Aug 02 '23 Sale 30.25 1,144 34,607 100,533 Aug 04 04:02 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite